October 23, 2026

Four Million Euros in EU Funding to Improve Prostate Cancer Care

Four Million Euros in EU Funding to Improve Prostate Cancer Care

A European research consortium led by the German Cancer Research Center (DKFZ) aims to fundamentally improve the diagnosis and treatment of prostate cancer using AI agents, big data, and patient-centered clinical decision support. The central goal is to detect aggressive tumors early and accurately, reduce unnecessary interventions, and tailor treatment decisions more closely to the individual patient. The European Commission is funding the “PROMETHEUS” consortium project with a total of four million euros over four years, of which 1.6 million euros will be allocated to the DKFZ.

Prostate cancer is the most common cancer among men. Although tumors detected at an early stage can be treated in curative intent, survival rates decrease considerably in advanced stages. At the same time, current unorganized screening practices result in many unnecessary biopsies and the diagnosis of tumors that do not require treatment.

PROMETHEUS* aims to address this clinical challenge. “With PROMETHEUS, we are taking precision oncology to the next level: moving away from isolated findings toward intelligent, multimodal, and explainable clinical decision support,” says Magdalena Görtz, research group leader at the DKFZ and consultant in urology at Heidelberg University Hospital. “If this allows us to reduce unnecessary interventions while simultaneously detecting aggressive prostate tumors at an early stage, it can in the long term improve patients’ quality of life, advance medical care in Europe, and relieve the burden on the healthcare system.”

PROMETHEUS was initiated by Magdalena Görtz, who now leads the European research consortium comprising six leading scientific and clinical institutions. Together, the partners contribute clinical expertise, state-of-the-art diagnostics, artificial intelligence, and large patient datasets.

Rather than focusing on individual clinical parameters in isolation, the EU consortium is developing an intelligent “multi-agent system”. Several specialized AI agents are being integrated within a collaborative framework. These AI agents analyze and integrate clinical patient data, multiparametric imaging, histopathological findings, and long-term oncological outcomes. This integration is intended to enable comprehensive and dynamic modeling of disease trajectories. In the future, the resulting decision-support system is intended to help physicians assess whether an intervention is necessary and which treatment strategy is best suited for each individual patient.

A particular focus of the project is on the explainability and trustworthiness of AI. The AI agents will be designed not only to provide predictions but also to provide comprehensible justifications and make uncertainties transparent. “We are not developing a black box, but rather a transparent, AI-supported agentic system that brings together medical knowledge, high-quality data and longitudinal disease trajectories and makes them accessible for clinical decision-making,” explains Görtz. In addition, PROMETHEUS generates synthetic medical data to facilitate data-privacy-compliant, cross-site AI development in Europe without the need to directly exchange sensitive patient data.

In addition to the DKFZ, the EU consortium includes the Erasmus Medical Center in Rotterdam, Heidelberg University Hospital, the Karolinska Institute in Stockholm, Radboud University Medical Center in Nijmegen, Umeå University, and PNO Innovation. The collaboration brings together interdisciplinary expertise from the fields of urology, radiology, oncology, epidemiology, data science, and AI to address highly relevant clinical questions in prostate cancer care. The close international network provides the basis for validating the AI system across several European clinical sites and, in the long term, integrating it into routine clinical practice.

An international Scientific Advisory Board and patient representatives ensure that the EIC PROMETHEUS project is not only technologically innovative, but also clinically relevant, patient-centered, and specifically geared toward medical application.

Through its EIC Pathfinder Program, the European Commission aims to identify new, innovative technologies with the potential to create future markets. To this end, visionary breakthrough projects at an early stage of technological development are funded.

*PROMETHEUS stands for “PROstate cancer Multimodal Explainable Transferable Holistic Expert for Universal Stratification.”

Our latest News

discover more
A Vaccine for Parkinson’s?

A Vaccine for Parkinson’s?

The Parkinson Foundation has awarded three Innovation Prizes for 2026, including—for the first time—the Manfred Moggert-Kemper Prevention Prize. Prof. Dr. Chi Wang Ip and Assistant Professor Dr. Rhonda McFleder from the Department of Neurology at the University Hospital of Würzburg (UKW), as well as Prof. Dr. Mathias Munschauer from the University Hospital of Heidelberg (UKHD), […]

Study from Heidelberg: Does Targeted Preparation Help with Recovery After Colon Cancer Surgery?

Study from Heidelberg: Does Targeted Preparation Help with Recovery After Colon Cancer Surgery?

Do patients recover more quickly after colorectal cancer surgery if they have previously completed a structured preparatory program? Researchers at Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital are investigating this question in the newly launched PREHAB-PEER study. The Federal Ministry of Research, Technology, and Space is funding the project with approximately 3.45 million […]

Building Better Sandwich Immunoassays: A Toolbox for Biopharma Development Teams

Building Better Sandwich Immunoassays: A Toolbox for Biopharma Development Teams

Immunoassay development used to just mean getting a classic plate-based ELISA up and running. Today, that “standard” ELISA has exploded into many antibody pair-based formats, from homogeneous TR‑FRET assays to multiplexed MSD or Luminex panels—each with its own advantages and pitfalls. The data these assays generate is more robust than ever, but so is the […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp